Pages that link to "Q40425060"
Jump to navigation
Jump to search
The following pages link to Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. (Q40425060):
Displayed 10 items.
- N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance (Q28471689) (← links)
- Optimal cytoplasmic transport in viral infections (Q28472404) (← links)
- Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data (Q28486299) (← links)
- A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. (Q33826904) (← links)
- Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms (Q36175788) (← links)
- Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors (Q36498272) (← links)
- HIV-1 drug resistance mutations: an updated framework for the second decade of HAART (Q36900010) (← links)
- Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. (Q37083800) (← links)
- Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation. (Q39519625) (← links)
- Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility. (Q41822419) (← links)